NRP1 and pancreatic adenocarcinoma: Increased expression of NRP1 and NRP2 was mainly associated with poor prognosis: NRP1 associated with poor OS for ACC, cervical & endocervical cancer (CESC), LGG, MESO, and STAD, while NRP2 associated with poor prognosis for bladder urothelial carcinoma (BLCA), KIRP, MESO, PAAD, and STAD, respectively.